Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Obinutuzumab
Trade Name Gazyva
Synonyms R7159|afutuzumab|GA101|GA-101|RO 5072759
Drug Descriptions

Gazyva (obinutuzumab) is a glycoengineered anti-CD20 antibody that binds to CD20 on B-cells, resulting in increased antibody-dependent cellular cytotoxicity and induction of apoptosis, and potentially leading to decreased growth of B-cell tumors (PMID: 20194898, PMID: 21220500). Gazyva (obinutuzumab) is FDA approved in combination with Ambochlorin (chlorambucil) for chronic lymphocytic leukemia and in combination with Treanda (bendamustine) or chemotherapy for follicular lymphoma (FDA.gov).

DrugClasses CD20 Antibody 6

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Acalabrutinib + Obinutuzumab Acalabrutinib Obinutuzumab 1 2
Acalabrutinib + Obinutuzumab + Venetoclax Acalabrutinib Obinutuzumab Venetoclax 0 3
Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab Aldesleukin Cyclophosphamide FT516 Fludarabine Obinutuzumab 0 1
Atezolizumab + Bendamustine + Obinutuzumab Atezolizumab Bendamustine Obinutuzumab 0 0
Atezolizumab + Bevacizumab + Obinutuzumab + RO6874281 Atezolizumab Bevacizumab Obinutuzumab RO6874281 0 1
Atezolizumab + Lenalidomide + Obinutuzumab Atezolizumab Lenalidomide Obinutuzumab 0 1
Atezolizumab + Obinutuzumab Atezolizumab Obinutuzumab 0 4
Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq Atezolizumab Obinutuzumab Polatuzumab vedotin-piiq 0 1
Atezolizumab + Obinutuzumab + RO6874281 Atezolizumab Obinutuzumab RO6874281 0 1
Atezolizumab + Obinutuzumab + RO6958688 Atezolizumab Obinutuzumab RO6958688 0 1
Bendamustine + Obinutuzumab Bendamustine Obinutuzumab 1 2
Bendamustine + Obinutuzumab + Parsaclisib Bendamustine Obinutuzumab Parsaclisib 0 1
Bendamustine + Obinutuzumab + Venetoclax Bendamustine Obinutuzumab Venetoclax 1 3
Chlorambucil + Obinutuzumab Chlorambucil Obinutuzumab 1 4
Chlorambucil + Obinutuzumab + Umbralisib Chlorambucil Obinutuzumab Umbralisib 0 1
Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + RO7082859 + Vincristine Cyclophosphamide Doxorubicin Obinutuzumab Prednisone RO7082859 Vincristine 0 1
Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Cyclophosphamide Doxorubicin Obinutuzumab Prednisone Vincristine 1 2
Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab Cyclophosphamide FT596 Fludarabine Obinutuzumab 0 1
Cyclophosphamide + Fludarabine + Obinutuzumab Cyclophosphamide Fludarabine Obinutuzumab 0 1
Duvelisib + Obinutuzumab Duvelisib Obinutuzumab 0 1
Entospletinib + Obinutuzumab Entospletinib Obinutuzumab 0 1
Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax Ibrutinib Lenalidomide Obinutuzumab Prednisone Venetoclax 0 1
Ibrutinib + Obinutuzumab Ibrutinib Obinutuzumab 0 7
Ibrutinib + Obinutuzumab + Venetoclax Ibrutinib Obinutuzumab Venetoclax 0 3
Idasanutlin + Obinutuzumab Idasanutlin Obinutuzumab 0 1
Idasanutlin + Obinutuzumab + Rituximab + Venetoclax Idasanutlin Obinutuzumab Rituximab Venetoclax 0 1
Idasanutlin + Obinutuzumab + Venetoclax Idasanutlin Obinutuzumab Venetoclax 0 1
Idelalisib + Obinutuzumab Idelalisib Obinutuzumab 0 1
Lenalidomide + Obinutuzumab Lenalidomide Obinutuzumab 0 1
Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq Lenalidomide Obinutuzumab Polatuzumab vedotin-piiq 0 1
Lenalidomide + Obinutuzumab + Venetoclax Lenalidomide Obinutuzumab Venetoclax 0 2
Obinutuzumab Obinutuzumab 0 9
Obinutuzumab + Otlertuzumab Obinutuzumab Otlertuzumab 0 1
Obinutuzumab + Pinatuzumab Vedotin + Rituximab Obinutuzumab Pinatuzumab Vedotin Rituximab 0 1
Obinutuzumab + Polatuzumab vedotin-piiq Obinutuzumab Polatuzumab vedotin-piiq 0 1
Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab Obinutuzumab Polatuzumab vedotin-piiq Rituximab 0 1
Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax Obinutuzumab Polatuzumab vedotin-piiq Venetoclax 0 1
Obinutuzumab + rhIL-15 Obinutuzumab rhIL-15 0 1
Obinutuzumab + RO7082859 + Tocilizumab Obinutuzumab RO7082859 Tocilizumab 0 1
Obinutuzumab + Umbralisib Obinutuzumab Umbralisib 0 1
Obinutuzumab + Vemurafenib Obinutuzumab Vemurafenib 0 1
Obinutuzumab + Venetoclax Obinutuzumab Venetoclax 1 5
Obinutuzumab + Venetoclax + Zanubrutinib Obinutuzumab Venetoclax Zanubrutinib 0 1
Obinutuzumab + Zanubrutinib Obinutuzumab Zanubrutinib 0 2


Additional content available in CKB BOOST